PLC β3 Polyclonal Antibody
- Catalog No.:YT3790
- Applications:WB;IHC;IF;ELISA
- Reactivity:Human;Mouse;Rat
- Target:
- PLCβ3
- Fields:
- >>Inositol phosphate metabolism;>>Metabolic pathways;>>Rap1 signaling pathway;>>Calcium signaling pathway;>>cGMP-PKG signaling pathway;>>Chemokine signaling pathway;>>Phosphatidylinositol signaling system;>>Sphingolipid signaling pathway;>>Phospholipase D signaling pathway;>>Adrenergic signaling in cardiomyocytes;>>Vascular smooth muscle contraction;>>Wnt signaling pathway;>>Apelin signaling pathway;>>Gap junction;>>Platelet activation;>>Neutrophil extracellular trap formation;>>NOD-like receptor signaling pathway;>>Circadian entrainment;>>Long-term potentiation;>>Retrograde endocannabinoid signaling;>>Glutamatergic synapse;>>Cholinergic synapse;>>Serotonergic synapse;>>Dopaminergic synapse;>>Long-term depression;>>Taste transduction;>>Inflammatory mediator regulation of TRP channels;>>Insulin secretion;>>GnRH signaling pathway;>>Estrogen signaling pathway;>>Melanogenesis;>>Thyroid hormone synthesis;>>Thyroid hormone signaling pathway;>>Oxytocin signaling pathway;>>Glucagon signaling p
- Gene Name:
- PLCB3
- Protein Name:
- 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-3
- Human Gene Id:
- 5331
- Human Swiss Prot No:
- Q01970
- Mouse Swiss Prot No:
- P51432
- Rat Swiss Prot No:
- Q99JE6
- Immunogen:
- The antiserum was produced against synthesized peptide derived from human PLC beta3. AA range:503-552
- Specificity:
- PLC β3 Polyclonal Antibody detects endogenous levels of PLC β3 protein.
- Formulation:
- Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
- Source:
- Polyclonal, Rabbit,IgG
- Dilution:
- WB 1:500 - 1:2000. IHC 1:100 - 1:300. IF 1:200 - 1:1000. ELISA: 1:5000. Not yet tested in other applications.
- Purification:
- The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
- Concentration:
- 1 mg/ml
- Storage Stability:
- -15°C to -25°C/1 year(Do not lower than -25°C)
- Other Name:
- PLCB3;1-phosphatidylinositol 4;5-bisphosphate phosphodiesterase beta-3;Phosphoinositide phospholipase C-beta-3;Phospholipase C-beta-3;PLC-beta-3
- Observed Band(KD):
- 140kD
- Background:
- This gene encodes a member of the phosphoinositide phospholipase C beta enzyme family that catalyze the production of the secondary messengers diacylglycerol and inositol 1,4,5-triphosphate from phosphatidylinositol in G-protein-linked receptor-mediated signal transduction. Alternative splicing results in multiple transcript variants.[provided by RefSeq, May 2010],
- Function:
- catalytic activity:1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate + H(2)O = 1D-myo-inositol 1,4,5-trisphosphate + diacylglycerol.,cofactor:Calcium.,function:The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes.,similarity:Contains 1 C2 domain.,similarity:Contains 1 PI-PLC X-box domain.,similarity:Contains 1 PI-PLC Y-box domain.,subunit:Interacts with SHANK2 (By similarity). Interacts with LPAR2.,
- Subcellular Location:
- Cytoplasm . Membrane . Nucleus . And particulate fractions. .
- Expression:
- Epithelium,Uterus,
Gut microbial co-metabolite 2-methylbutyrylcarnitine exacerbates thrombosis via binding to and activating integrin α2β1 Cell Metabolism Kan Huang WB Rat 1:1000 plasma
- June 19-2018
- WESTERN IMMUNOBLOTTING PROTOCOL
- June 19-2018
- IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL
- June 19-2018
- IMMUNOFLUORESCENCE PROTOCOL
- September 08-2020
- FLOW-CYTOMEYRT-PROTOCOL
- May 20-2022
- Cell-Based ELISA│解您多样本WB检测之困扰
- July 13-2018
- CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN
- July 13-2018
- CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN
- July 13-2018
- Antibody-FAQs
- Products Images
- Western Blot analysis of various cells using PLC β3 Polyclonal Antibody
- Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue, using PLC beta3 Antibody. The picture on the right is blocked with the synthesized peptide.